Observed Signal · Jul 14, 2026 · Funding · Source: techcrunch · Impact: 2/5 · Sentiment: Neutral
IM8 Takes $1B From General Catalyst's CVF Fund
IM8, a vitamin drink startup associated with David Beckham and owned by Prenetics, has taken $1 billion in funding from General Catalyst’s Customer Value Fund (CVF). CVF provides non-dilutive, loan-like financing instead of equity: startups repay the principal plus a fixed, capped percentage of revenue (termed “reference income”). The IM8 financing is structured to cover up to 70% of customer acquisition costs; General Catalyst will not take an ownership stake and IM8’s equity will not be diluted. Once GC recovers its investment and hits the capped revenue share, subsequent revenue from those customers will go to Prenetics. IM8 sells its product via subscriptions and was co-founded by CEO Danny Yeung.
Large, non-dilutive $1B financing demonstrates an alternative revenue-linked funding model for subscription D2C brands and could influence how high-ARPU consumer businesses finance customer acquisition, but it is not directly industry-shifting for AdTech/MarTech.
Track General Catalyst Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- General Catalyst’s Customer Value Fund provided $1 billion to IM8.
- CVF’s investment is non-dilutive: it takes no equity and is repaid via a capped share of revenue ("reference income").
- The loan finances up to 70% of IM8’s customer acquisition costs.
- IM8 is a subsidiary owned by Prenetics and was co-founded by CEO Danny Yeung.
- IM8 sells a subscription vitamin drink linked to longevity compounds and is associated with David Beckham.
Connected Companies & Entities
2 Entities mapped“David Beckham’s startup IM8 has taken on $1 billion in funding from General Catalyst’s Customer Value Fund (CVF), the company announced on T...”
“As we previously reported, Grammerly also took [$1 billion] from GC’s CVF in May 2025, just prior to acquiring Superhuman....”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
IVP Seeks $1.8B Fund, Reports 31.1% Net IRR
Institutional Venture Partners (IVP) is raising $1.8 billion for its 19th flagship fund and tells prospective limited partners it has generated a 31.1% net internal rate of return since its 1980 founding. Fund documents reviewed by Newcomer show IVP is seeking premium economics — 2% management fee in year one, 2.25% thereafter, 25% carry stepping to 30% after a 2.5x hurdle, and a 3% GP commitment. The firm’s historical performance includes a 1996 fund that returned 6.7x net DPI (94.5% IRR); more recent vintages range from 1.2x net TVPI (2024) to 2.0x DPI (2015 vintage, 22.7% IRR). IVP highlights investments such as Perplexity, Baseten, ClickHouse, Chainguard, and Abridge, notes a major but not largest Anthropic stake, and appears to have missed OpenAI and SpaceX.
Bain Capital Ventures Raises $1.6B Fund for Post-AGI Era Startups
Bain Capital Ventures (BCV) has raised a new $1.6 billion fund, 14% larger than its previous $1.4 billion fund from three years ago. The firm plans to deploy the capital primarily into startups focused on AI, particularly in infrastructure, healthcare, physical AI, and security, which it calls the 'post-AGI era.' BCV aims to fund compute infrastructure until AI becomes 'too cheap to meter,' and cites portfolio company Crusoe, a data center developer valued at $30 billion and a near-term IPO candidate. The firm also highlights investments in Loyal, a pet longevity startup, and Dream, an AI-powered national infrastructure defender. BCV intends to invest in 30 to 40 companies, primarily at seed through Series B stages, leveraging Bain Capital's expertise in credit, real estate, insurance, and private equity to support founders with more than just equity capital.
UTIMCO Shows Massive VC IRRs Driven by AI Bets
UTIMCO's latest disclosures through November 30, 2025 reveal extreme concentration of recent venture returns driven by early-stage stakes in leading AI companies. Thrive Capital’s 2022 Fund VIII is showing an IRR of roughly 126%, attributed to early investments in OpenAI, Cursor and Base Power, while some Thrive funds and a 2024 venture fund show divergent performance. Notable Capital (still recorded as GGV Capital) saw a core 2023 fund IRR swing from -48% to about 96%, driven largely by Anthropic and Fal. Sequoia’s 2020–2021 vintages have improved, whereas HongShan and Peak XV vintages lag. The article cautions these IRRs are mainly markups on private valuations (paper gains) and could change if market conditions reverse.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.